Abacus dx ASDG 2022 Showcase

Products are for Professional/Laboratory use only

Abacus dx creates value by connecting innovative global suppliers with Australasian customers. Visit our stand to find out more about our solutions for human genetics testing (inherited or acquired), the latest technologies, and innovations in molecular and cytogenetic diagnostics.

Abacus dx is proud to partner with high quality molecular diagnostics manufacturers including: Devyser, Invivoscribe, Asuragen, ZytoVision and Biocartis.

Biocartis provides fully integrated and broadly applicable molecular diagnostics. The Idylla is Biocartis’ fully automated, real-time PCR-based molecular diagnostics system which provides fast access to highly reliable clinical molecular diagnostic information. The Idylla can detect BRAF V600E, E2, D, K, R and M mutations within 90 minutes.

Devyser are specialists when it comes to complex DNA testing within hereditary diseases and oncology with products used to guide targeted cancer therapies and enable rapid prenatal diagnostics. Included in their portfolio is the BRCA NGS kit for detection of BRCA1 and BRCA2 in germline and somatic samples as well as the Fetal RHD kit used to determine fetal RHD status from maternal plasma.

Asuragen’s molecular assays are designed to provide streamlined workflow and ease of use and is comprised of two product portfolios; Genetics and Oncology. The genetics portfolio includes assays aiding in the detection of the FMR1 and C9orf72 gene, while the Oncology assays use molecular methods ranging from qPCR to NGS to assist our understanding of cancer.

ZytoVision develop and produce innovative in vitro diagnostic products, primarily for tumour diagnosis, based on the technique of in situ hybridization using FISH and CISH techniques.

Invivoscribe provides a comprehensive selection of PCR-based gene rearrangement, chromosome translocation, and gene mutation Research Use Only testing reagents and controls. They also provide CE-marked in vitro diagnostic products that are used to identify, classify and monitor leukemias, lymphomas and other lymphoproliferative diseases.